Search

Your search keyword '"Germonpre, Paul"' showing total 24 results
Start Over Author "Germonpre, Paul"
24 results on '"Germonpre, Paul"'

1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

2. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Author

Pall, Georg, Surmont, Veerle, Bosquee, Léon, Germonpré, Paul, Brückl, Wolfgang, Grah, Christina, Herzmann, Christian, Leistner, Rumo, Meyer, Andreas, Müller, Lothar, Schmalz, Oliver, Scholz, Christian, Schröder, Michael, Serke, Monika, Wesseler, Claas, Brandts, Christian, Kopp, Hans-Georg, Blau, Wolfgang, Griesinger, Frank, Campelo, Maria Rosario Garcia, Garcia, Yolanda Garcia, Perez, José Manuel Trigo, Thomas, M., Ponce-Aix, S., Navarro, A., Riera-Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Dómine Gómez, M., Kollmeier, J., Sadjadian, P., Fröhling, K -P, Huber, R.M., and Wolf, M.

Published
2018
Full Text
View/download PDF

5. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Author

Herbst, Roy S, Sun, Yan, Eberhardt, Wilfried EE, Germonpré, Paul, Saijo, Nagahiro, Zhou, Caicun, Wang, Jie, Li, Longyun, Kabbinavar, Fairooz, Ichinose, Yukito, Qin, Shukui, Zhang, Li, Biesma, Bonne, Heymach, John V, Langmuir, Peter, Kennedy, Sarah J, Tada, Hiroomi, and Johnson, Bruce E

Published
2010
Full Text
View/download PDF

6. Postextubation obstructive pseudomembranes: a case series and review of a rare complication after endotracheal intubation

Author

Lins, Muriel, Dobbeleir, Itte, Germonpre, Paul, Waelput, Wim, Pauwels, Patrick, and Jorens, Philippe G.

Subjects
Fibrin -- Analysis, Fiber optics -- Equipment and supplies, Health
Abstract

Endotracheal intubation obviously may be lifesaving, but it may also lead to complications, including those related to damage of the airways. Superficial damage of the trachea at the site of the endotracheal cuff may trigger the formation of an obstructive fibrinous tracheal pseudomembrane (OFTP). Shortly after extubation, this clot, consisting of fibrin, leucocytes, and necrotic epithelium, can cause stridor due to adherence to the tracheal wall and obstruction of the airway. In most cases, the lesion is easily removed by rigid or fiberoptic bronchoscopy and virtually never leads to permanent damage. The study consisted of case series and review of the literature. This report describes a series of five adult cases and reviews all 19 other previously described cases. A careful analysis of all reported cases, however, did not highlight a simple predisposing factor or illness. It is important to consider OFTP in the differential diagnosis of stridor and respiratory insufficiency in the postextubation period. Keywords Extubation * Tracheal obstruction * Obstructive fibrinous tracheal pseudomembrane, Introduction Endotracheal intubation may obviously be life-saving, but may also lead to complications, including those related to damage of airways [1, 2]. Superficial tracheal damage can lead to a local, [...]

Published
2011
Full Text
View/download PDF

11. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus

Author

Cappuzzo, Federico, Moro-Sibilot, Denis, Gautschi, Oliver, Boleti, Ekaterini, Felip, Enriqueta, Groen, Harry J. M., Germonpre, Paul, Meldgaard, Peter, Arriola, Edurne, Steele, Nicola, Fox, Jesme, Schnell, Patrick, Engelsberg, Arne, Wolf, Juergen, Cappuzzo, Federico, Moro-Sibilot, Denis, Gautschi, Oliver, Boleti, Ekaterini, Felip, Enriqueta, Groen, Harry J. M., Germonpre, Paul, Meldgaard, Peter, Arriola, Edurne, Steele, Nicola, Fox, Jesme, Schnell, Patrick, Engelsberg, Arne, and Wolf, Juergen

Abstract

Within 4 years of the discovery of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC), the ALK inhibitor crizotinib gained US and European approval for the treatment of advanced ALK-positive NSCLC. This was due to the striking response data observed with crizotinib in phase I and II trials in patients with ALIC-positive NSCLC, as well as the favorable tolerability and safety profile observed. Recently published phase III data established crizotinib as a new standard of care for this NSCLC molecular subset. A consequence of such rapid approval, however, is the limited clinical experience and relative paucity of information concerning optimal therapy management. In this review, we discuss the development of crizotinib and the clinical relevance of its safety profile, examining crizotinib-associated adverse events in detail and making specific management recommendations. Crizotinib-associated adverse events were mostly mild to moderate in severity in clinical studies, and appropriate monitoring and supportive therapies are considered effective in avoiding the need for dose interruption or reduction in most cases. Therapy management of patients following disease progression on crizotinib is also discussed. Based on available clinical data, it is evident that patients may have prolonged benefit from crizotinib after Response Evaluation Criteria in Solid Tumors-defined disease progression, and crizotinib should be continued for as long as the patient derives benefit. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.

Published
2015

12. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Author

Rolfo, Christian, primary, Giovannetti, Elisa, additional, Hong, David S., additional, Bivona, T., additional, Raez, Luis E., additional, Bronte, Giuseppe, additional, Buffoni, Lucio, additional, Reguart, Noemí, additional, Santos, Edgardo S., additional, Germonpre, Paul, additional, Taron, Mìquel, additional, Passiglia, Francesco, additional, Van Meerbeeck, Jan P., additional, Russo, Antonio, additional, Peeters, Marc, additional, Gil-Bazo, Ignacio, additional, Pauwels, Patrick, additional, and Rosell, Rafael, additional

Published
2014
Full Text
View/download PDF

14. Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

Author

UCL - SSH/IMAQ - Institut multidisciplinaire pour la modélisation et l'analyse quantitative, Hollevoet, Kevin, Nackaerts, Kristiaan, Thimpont, Joel, Germonpre, Paul, Bosquee, Lionel, De Vuyst, Paul, Legrand, Catherine, Kellen, Eliane, Kishi, Yoshiro, Delanghe, Joris R., van Meerbeeck, Jan P., UCL - SSH/IMAQ - Institut multidisciplinaire pour la modélisation et l'analyse quantitative, Hollevoet, Kevin, Nackaerts, Kristiaan, Thimpont, Joel, Germonpre, Paul, Bosquee, Lionel, De Vuyst, Paul, Legrand, Catherine, Kellen, Eliane, Kishi, Yoshiro, Delanghe, Joris R., and van Meerbeeck, Jan P.

Abstract

Rationale: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF), which originates from the same precursor protein, is potentially more sensitive, yet lacks validation. Objectives: To analyze the diagnostic performance of MPF as an MPM biomarker and compare this performance with SM. Methods: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85). Sera were analyzed for SM and MPF levels using the Mesomark and Human MPF ELISA kit, respectively. Measurements and Main Results: SM and MPF levels differed significantly between patients with M PM and participants from each other cohort (P < 0.001). Receiver operating characteristics curve analysis did not reveal a significant difference between both markers in area under curve (AUC) for distinguishing MPM from all cohorts jointly (SM = 0.871, MPF = 0.849; P = 0.28). At 95% specificity, SM and MPF had a sensitivity of 64% (cutoff = 2.00 nmol/L) and 68% (cutoff = 12.38 ng/ml), respectively. Combining both markers did not improve the diagnostic performance. Conclusions: In this prospective multicenter study, MPF is validated as a highly performant MPM biomarker. The similar AUC values of SM and MPF, together with the limited difference in sensitivity, show that both serum biomarkers have an equivalent diagnostic performance.

Published
2010

15. Validation of soluble mesothelin: design and preliminary results of a Belgian multicentric observational study

Author

UCL - EUEN/STAT - Institut de statistique, Hollevoet, Kevin, Kellen, Eliane, Nackaerts, Kristiaan, Thimpont, Joel, Germonpre, Paul, De Vuyst, Paul, Bosquee, Lionel, Delanghe, Joris, Legrand, Catherine, van Meerbeeck, Jan P., UCL - EUEN/STAT - Institut de statistique, Hollevoet, Kevin, Kellen, Eliane, Nackaerts, Kristiaan, Thimpont, Joel, Germonpre, Paul, De Vuyst, Paul, Bosquee, Lionel, Delanghe, Joris, Legrand, Catherine, and van Meerbeeck, Jan P.

Published
2009

23. Endobronchial Lipomas.

Author

Pollefliet, Christophe, Peters, Kevin, Janssens, Annelies, Luijks, Antonia, Van Bouwel, Erik, Van Marck, Eric, and Germonpre, Paul

Published
2009
Full Text
View/download PDF

24. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Author

Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, and Pauwels P

Abstract

The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of "oncogenic drivers" and the subsequent development of targeted therapies. The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC and the subsequent clinical development of crizotinib has been an amazing success story in lung cancer translational-research, and its accelerated approval [only 4 years from the discovery of ALK rearrangement in NSCLC to the approval by the Food and Drug Administration (FDA)] marked the beginning of the new decade of targeted therapy. However, common to all targeted therapies, despite an initial benefit, patients inevitably experience tumor progression, due to the development of resistance. Several molecular mechanisms are responsible for acquired resistance, such as secondary mutations of ALK kinase domain or amplification of ALK fusion gene, or the activation of other oncogenic drivers, which may cause resistance independently of ALK genetic alterations. Pre-clinical data and early clinical trials showed the promising efficacy of a new class of ALK-inhibitors in overcoming acquired resistance. The inhibition of the molecular chaperone, HSP90, represents another promising strategy to overcome crizotinib resistance in ALK-rearranged NSCLC. Several molecules are currently under investigation in order to establish their specific role in the treatment of ALK-rearranged NSCLC.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results